Skip to main content
. 2022 Dec 26;14(4):e00560. doi: 10.14309/ctg.0000000000000560

Figure 2.

Figure 2.

Effects of ABX464 on peripheral blood mononuclear cells (PBMCs). Cells were treated for 6 days with 5 μM ABX464. (a) Cytokine concentrations in the supernatant of PBMCs. (b) Th1/Th17 cells (CD196/CD183 expression) among viable CD4+ cells. (c) Intracellular IFNγ and IL17a expression among viable CD4+ cells. (d) Correlation between miR-124 modulation and Th17-cell inhibition in PBMCs related to ABX464 concentration. Cells were treated for 6 days with different concentrations of ABX464 (not above 10 μM to avoid a cytotoxic effect). Th17-cell inhibition and fold changes in miR-124 were determined in comparison with DMSO-treated cells as a negative control. Mean ± SD are reported. Results were obtained on PBMC isolated from 15 or 16 healthy blood donors and 5 different experiments (panel a), from 11 donors and 3 experiments (panel b), and from 16 donors and 5 experiments (panel c). Dots represent blood samples from different, and mean ± SEM are reported. Dunnett or Dunn test (ns = P > 0.05, *P < 0.05, ***P < 0.001, ****P < 0.0001).